This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.
Clinical Question
How does the evidence characterize the efficacy, mechanism, and regulatory status of Semax for neuroprotection and ischemic stroke treatment?
Evidence Snapshot
- Compound Type: Synthetic heptapeptide analog of the ACTH(4-10) fragment.
- Evidence Grade: B.
- Primary Indications: Ischemic stroke (clinically used in Russia since the 1990s).
- Key Validation: fMRI validation and 25+ years of status as a standard stroke treatment in Russia.
- Regulatory Status: Approved in Russia; not FDA-approved. Reviewed by the FDA Pharmacy Compounding Advisory Committee (PCAC) in July 2026.
What the Research Shows
Semax is a synthetic analog of the adrenocorticotropic hormone (ACTH) fragment 4-10. It has been utilized as a standard clinical treatment for ischemic stroke in Russia for over 25 years. Research including fMRI validation supports its role in neuroprotection.
Data indicates that while Semax is derived from an ACTH fragment, it does not produce hormonal or adrenal side effects. Despite its long-standing clinical history in Russia, there is very limited Western validation for the compound. It has not been evaluated in large-scale Western randomized controlled trials (RCTs).
Mechanism
According to mechanistic data, Semax functions through the following pathways:
- BDNF Upregulation: The peptide upregulates brain-derived neurotrophic factor (BDNF).
- Neurotransmitter Modulation: It modulates both the dopaminergic and serotonergic systems.
- Neuroprotection: The compound provides neuroprotective effects without the systemic hormonal impact typically associated with ACTH.
Limitations of the Evidence
The primary limitation of the current evidence base is the geographic disparity in clinical data. While Russia has utilized the peptide in standard stroke care since the 1990s, there is a lack of data from Western clinical environments. No large-scale Western RCTs have been conducted to date.
From a regulatory standpoint, the FDA has identified several safety concerns, including potential immunogenicity, aggregation, and peptide-related impurities. The FDA also notes that there is limited human safety information available in the domestic regulatory context. A warning letter was issued in 2020 regarding this compound to Tailor Made Compounding.
Clinical Takeaway
Semax has a Grade B evidence rating, supported by over two decades of clinical use in Russia for ischemic stroke and fMRI-based evidence of its neuroprotective mechanisms. However, it remains non-FDA approved, and the agency has expressed concerns regarding impurities and immunogenicity. Physicians should note that while it is an ACTH analog, it is characterized by an absence of adrenal side effects in the provided literature.
For clinicians interested in neuroprotective research, it may be beneficial to find a doctor who specializes in evaluating international clinical data. When discussing emerging research with a peptide doctor, it is important to consider the current FDA PCAC review status and the 2020 warning letters associated with this compound.
Sources
- TruthTides Peptide Database: Semax [Grade: B]
- FDA Pharmacy Compounding Advisory Committee (PCAC) Meeting, July 23-24, 2026
- FDA Regulatory Review, September 27, 2026
- FDA Warning Letter, 2020 (Tailor Made)
Referenced Peptides
This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.